Tempus Launches Minimal Residual Disease Test Portfolio
Key Highlights Clinical launch of MRD test portfolio featuring xM and xM (NeXT Personal® Dx) tests. Tumor-naïve and tumor-informed assays designed for…
Browsing Tag
Personalis Inc.
1 post